{"paper_id": "0d6578570cccb074e98edee339334b26dd7dc2f8", "metadata": {"title": "Systematic investigations of COVID-19 in 283 cancer patients Correspondence to: Abstracts", "authors": [{"first": "Jie", "middle": [], "last": "Wang", "suffix": "", "affiliation": {"laboratory": "State Key Laboratory of Molecular Oncology", "institution": "", "location": {"settlement": "Chinese"}}, "email": ""}, {"first": "Qibin", "middle": [], "last": "Song", "suffix": "", "affiliation": {"laboratory": "State Key Laboratory of Molecular Oncology", "institution": "", "location": {"settlement": "Chinese"}}, "email": ""}, {"first": "Yuan", "middle": [], "last": "Chen", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University 16 of Science and Technology", "location": {"postCode": "430030", "settlement": "Wuhan", "region": "Hubei", "country": "China"}}, "email": ""}, {"first": "Zhijie", "middle": [], "last": "Wang", "suffix": "", "affiliation": {"laboratory": "State Key Laboratory of Molecular Oncology", "institution": "", "location": {"settlement": "Chinese"}}, "email": ""}, {"first": "Qian", "middle": [], "last": "Chu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University 16 of Science and Technology", "location": {"postCode": "430030", "settlement": "Wuhan", "region": "Hubei", "country": "China"}}, "email": ""}, {"first": "Hongyun", "middle": [], "last": "Gong", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Shangli", "middle": [], "last": "Cai", "suffix": "", "affiliation": {"laboratory": "", "institution": "Burning Rock Biotech", "location": {"addrLine": "17", "postCode": "510300", "settlement": "Guangzhou", "country": "China"}}, "email": ""}, {"first": "Xiaorong", "middle": [], "last": "Dong", "suffix": "", "affiliation": {"laboratory": "", "institution": "Tongji Medical College", "location": {}}, "email": ""}, {"first": "Bin", "middle": [], "last": "Xu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Weidong", "middle": [], "last": "Hu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Zhongnan Hospital of Wuhan University", "location": {"addrLine": "Wuhan, Hubei 20 430071", "country": "China"}}, "email": ""}, {"first": "Qun", "middle": [], "last": "Wang", "suffix": "", "affiliation": {"laboratory": "", "institution": "The Fifth Hospital of Wuhan", "location": {"addrLine": "Wuhan, Hubei 21 430050", "country": "China"}}, "email": ""}, {"first": "Linjun", "middle": [], "last": "Li", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University 16 of Science and Technology", "location": {"postCode": "430030", "settlement": "Wuhan", "region": "Hubei", "country": "China"}}, "email": ""}, {"first": "Jiyuan", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yang", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhibin", "middle": [], "last": "Xie", "suffix": "", "affiliation": {"laboratory": "", "institution": "Yangtze University", "location": {"postCode": "434023", "settlement": "Jingzhou", "region": "Hubei", "country": "China"}}, "email": ""}, {"first": "Zhiguo", "middle": [], "last": "Luo", "suffix": "", "affiliation": {"laboratory": "", "institution": "Hubei University of Medicine", "location": {"postCode": "442000", "settlement": "Shiyan", "region": "Hubei", "country": "China"}}, "email": ""}, {"first": "Jing", "middle": [], "last": "Liu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huanggang Central Hospital", "location": {"addrLine": "Huanggang, Hubei 438000, 28 China", "postCode": "13"}}, "email": ""}, {"first": "Xiuli", "middle": [], "last": "Luo", "suffix": "", "affiliation": {"laboratory": "", "institution": "Academy of Medical Sciences & Peking Union Medical College", "location": {"addrLine": "14 2 Cancer Center", "postCode": "100021", "settlement": "Beijing", "country": "China"}}, "email": ""}, {"first": "Jie", "middle": [], "last": "Ren", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhiguo", "middle": [], "last": "Rao", "suffix": "", "affiliation": {"laboratory": "", "institution": "Burning Rock Biotech", "location": {"addrLine": "17", "postCode": "510300", "settlement": "Guangzhou", "country": "China"}}, "email": ""}, {"first": "Xinhua", "middle": [], "last": "Xu", "suffix": "", "affiliation": {"laboratory": "", "institution": "HuBei University of Medicine", "location": {"addrLine": "33 China, 17, 34 Suizhou, Hubei 441300", "postCode": "443003", "settlement": "Yichang", "region": "Hubei", "country": "China"}}, "email": ""}, {"first": "Dongfeng", "middle": [], "last": "Pan", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zuowei", "middle": [], "last": "Hu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University of Science and Technology", "location": {"postCode": "430022", "settlement": "Wuhan", "region": "Hubei", "country": "China"}}, "email": ""}, {"first": "Gang", "middle": [], "last": "Feng", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University of Science and Technology", "location": {"addrLine": "36 Tongji Medical College, Wuhan, Hubei 37 430000", "country": "China"}}, "email": ""}, {"first": "Chiding", "middle": [], "last": "Hu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Affiliated Hospital of Jianghan University", "location": {"addrLine": "38 Wuhan, Hubei 430015", "country": "China"}}, "email": ""}, {"first": "Liqiong", "middle": [], "last": "Luo", "suffix": "", "affiliation": {"laboratory": "", "institution": "Tongji Medical College", "location": {}}, "email": ""}, {"first": "Hongda", "middle": [], "last": "Lu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Tongji Medical College", "location": {"addrLine": "41"}}, "email": ""}, {"first": "Ruizhi", "middle": [], "last": "Ran", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jun", "middle": [], "last": "Jin", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yanhua", "middle": [], "last": "Xu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yong", "middle": [], "last": "Yang", "suffix": "", "affiliation": {"laboratory": "of WISCO (Wuhan Iron and Steel Corporation)", "institution": "The Second Hospital", "location": {"addrLine": "Wuhan, Hubei 430085, China, 47 27, Jingzhou, Hubei 434300, 48 China", "postCode": "28"}}, "email": ""}, {"first": "Zhihong", "middle": [], "last": "Zhang", "suffix": "", "affiliation": {"laboratory": "", "institution": "Zhongnan Hospital of Wuhan University", "location": {"addrLine": "Wuhan, Hubei 20 430071", "country": "China"}}, "email": ""}, {"first": "Li", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Kuang", "middle": [], "last": "28", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Runkun", "middle": [], "last": "Wang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Youhong", "middle": [], "last": "Dong", "suffix": "", "affiliation": {"laboratory": "", "institution": "Hubei University of Medicine", "location": {"addrLine": "51 Xiangyang No.1 People's Hospital, Xiangyang, Hubei 52 441000", "country": "China"}}, "email": ""}, {"first": "Jianhai", "middle": [], "last": "Sun", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Wenbing", "middle": [], "last": "Hu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huangshi Central Hospital of EDong", "location": {"addrLine": "54 Healthcare, Huangshi, Hubei 435000", "country": "China"}}, "email": ""}, {"first": "Tienan", "middle": [], "last": "Yi", "suffix": "", "affiliation": {"laboratory": "", "institution": "The Fifth Hospital of Wuhan", "location": {"addrLine": "Wuhan, Hubei 21 430050", "country": "China"}}, "email": ""}, {"first": "Hanlin", "middle": [], "last": "Wu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Mingyu", "middle": [], "last": "Liu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jiachen", "middle": [], "last": "Xu", "suffix": "", "affiliation": {"laboratory": "State Key Laboratory of Molecular Oncology", "institution": "", "location": {"settlement": "Chinese"}}, "email": ""}, {"first": "Jianchun", "middle": [], "last": "Duan", "suffix": "", "affiliation": {"laboratory": "State Key Laboratory of Molecular Oncology", "institution": "", "location": {"settlement": "Chinese"}}, "email": ""}, {"first": "Zhengyi", "middle": [], "last": "Zhao", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Guoqiang", "suffix": "", "affiliation": {"laboratory": "", "institution": "Burning Rock Biotech", "location": {"addrLine": "17", "postCode": "510300", "settlement": "Guangzhou", "country": "China"}}, "email": ""}, {"first": "Wang", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yu", "middle": [], "last": "Xu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jie", "middle": [], "last": "He", "suffix": "", "affiliation": {"laboratory": "State Key Laboratory 59 of Molecular Oncology", "institution": "", "location": {"postCode": "100021", "settlement": "Beijing", "country": "China"}}, "email": ""}]}, "abstract": [], "body_text": [{"text": "Since the publicly reported coronavirus disease 2019 caused by severe acute 111 respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in December, 2019 1 and the 112 subsequent evidences of its human-to-human transmission property released in January 113 2020, 2 there has been an extremely rapid spread of the novel coronavirus around the globe. 114 The World Health Organization (WHO) has declared a global health emergency on January Cancer patients, as a special population who usually have a high demand for 121 intensive care and are frequently systematically immunosuppressed, are considered to be 122 more susceptible to the infection. 6 Accordingly, a considerable amount of cancer patients 123 may have been subjected to COVID-19 during the pandemic, which has attracted 124 increasing attention from the clinicians. [6] [7] [8] [9] Recent studies with small cohorts (n = 12 to 28) 125 of SARS-CoV-2 infected cancer patients have proposed the potentially higher 126 susceptibility and poorer prognosis of COVID-19 in cancer patients compared to the 127 overall population. 6, 8, 10 However, the study population in these reports are too limited to 128 provide conclusive evidences, and the characteristics of COVID-19 in cancer patients 129 remained largely unknown. Herein, we carried out the present large retrospective study for 130 the comprehensive investigation of the clinical characteristics, prognosis, survival status, 131 and potential risk factors of severe events of COVID-19 in a large cohort of Chinese cancer 132 patients.", "cite_spans": [{"start": 351, "end": 354, "text": "114", "ref_id": null}, {"start": 648, "end": 649, "text": "6", "ref_id": null}, {"start": 831, "end": 834, "text": "[6]", "ref_id": null}, {"start": 835, "end": 838, "text": "[7]", "ref_id": null}, {"start": 839, "end": 842, "text": "[8]", "ref_id": null}, {"start": 843, "end": 846, "text": "[9]", "ref_id": null}, {"start": 1087, "end": 1089, "text": "6,", "ref_id": null}, {"start": 1090, "end": 1092, "text": "8,", "ref_id": null}, {"start": 1093, "end": 1095, "text": "10", "ref_id": null}, {"start": 1443, "end": 1446, "text": "131", "ref_id": null}], "ref_spans": [], "section": "110"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "133"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. and further reviewed and confirmed by two independent physicians from each hospital.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The data were analyzed by two independent statisticians (GW and YuXu). All 153 inconsistencies were reviewed and confirmed by the Medical Review Board composed of 154 physicians from departments of oncology, thoracic surgery, and pulmonary and critical care 155 medicine. Patient identity protection was maintained throughout the study. ", "cite_spans": [], "ref_spans": [], "section": "152"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)", "cite_spans": [], "ref_spans": [], "section": "157"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. CoV-2 until death due to any cause.", "cite_spans": [], "ref_spans": [], "section": "157"}, {"text": "The clinical pathological variables, symptoms, and chest CT scan results in the patients 176 were statistically described. Continuous variables were described by median (IQR) and 177 categorical variables were described by number (percentages). To assess the differences 178 between different subset of population, Mann-Whitney test was performed for continuous 179 variables and chi-square test was performed for categorical variables. For hospitalization 180 stay, Kaplan-Meier curves were plotted and compared by using a log-rank test with 181 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "175"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. ", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "A total of 283 cancer patients who were admitted to 33 designated hospitals with laboratory 196 confirmed diagnosis of COVID-19 were included in the study ( Table 1) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [{"start": 157, "end": 165, "text": "Table 1)", "ref_id": "TABREF4"}], "section": "195"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. . https://doi.org/10.1101/2020.04.28.20083246 doi: medRxiv preprint 8 (49%) with locally advanced or advanced diseases. Compared with the former cancer 206 patients, the current cancer patients were more likely to exhibit severe symptoms (29% vs 207 17%) on admission.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The most common symptoms on admission were fever (73%), cough (68%), fatigue 209 (49%), sputum (41%), and dyspnea (40%) (supplementary table S1). Baseline chest CT ", "cite_spans": [], "ref_spans": [], "section": "208"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "228"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. with recent chemotherapy (33%), followed by surgery (26%), other treatments (19%), and 252 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. The rapid spreading of COVID-19 has swept the globe, leading to a worldwide pandemic.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The present study has provided the first comprehensive depiction of the clinicopathological CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "272"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. the studied cohort (6.0%, 3.2% for leukemia and 3.5% for lymphoma), which almost 293 doubles that of the prevalence of LHM in the overall cancer population in China (3.8%, 294 1.8% for leukemia and 2.1% for lymphoma), 13 indicating that these patients may be more 295 susceptible to SARS-CoV-2 infection. In addition, an even higher rate of death cases was 296 observed in patients with LHM (53%) compared with the patients with solid tumors (18%), 297 and all of the LHM patients who were treated with recent chemotherapy died. Collectively, 298 our results further suggested that the worse outcomes in SARS-CoV-2 infected cancer 299 patients may be attributed to both the intrinsic immunocompromised status from the 300 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. . https://doi.org/10.1101/2020.04.28.20083246 doi: medRxiv preprint 12 malignancies and the immunosuppression caused by active anti-tumor treatments.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "Accordingly, anti-tumor treatment, especially chemotherapy, should be used with great 302 caution to reduce the potential negative effects on the patients. 303 Previous reports suggested that age and coexisting conditions were potential risk 304 factors associated with disease severity. 14-16 Given the higher median age in our cancer 305 cohort (63 years) than the reported median age of 47-year-old in the general COVID-19 306 patients, the effect of age on the disease severity was weakened, providing a relatively 307 lower level of significance (OR, 1.94, 95%CI 1.12-3.37) in the univariable analysis 308 compared to the other variables (table 2). Our study further showed that LHM, an elevated 309 baseline neutrophil, DBIL, creatinine, troponin, and the severe symptoms at onset illness 310 were independently associated with the development of critical or death cases in cancer 311 patients with COVID-19, which may provide important implications for the patient cares.", "cite_spans": [{"start": 156, "end": 159, "text": "303", "ref_id": null}], "ref_spans": [], "section": "301"}, {"text": "There are several limitations in this study. Firstly, this study was conducted in a 313 retrospective setting. Nevertheless, the patient population in this study was relatively large, 314 and the patients were consecutively included irrespective of their baseline characteristics 315 including the clinical symptoms, which will reduce the potential bias of the study 316 population. Secondly, this study focused on the investigation of patients with cancer 317 infected with SARS-CoV-2, and no direct comparison was conducted between the infected 318 cancer patients and the non-cancer patients. Despite that, comparisons have been made 319 between the current and the former cancer patients, who were considered to exhibit 320 relatively more likely to cancer-free patients as a reference. Besides, the studied population 321 came from as many as 33 designated hospitals in Hubei province, China, which is 322 considered to be fairly representative for the overall condition of COVID-19 cancer 323 patients in Hubei province, and thus was compared with the data of general COVID-19 324 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "312"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. . https://doi.org/10.1101/2020.04.28.20083246 doi: medRxiv preprint 13 patients in Hubei province over the same period. ", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "348"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. . https://doi.org/10. 1101 /2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [{"start": 94, "end": 98, "text": "1101", "ref_id": null}, {"start": 99, "end": 104, "text": "/2020", "ref_id": "BIBREF2"}], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020 . . https://doi.org/10.1101 /2020 Chemotherapy 46 (16) 0 (0) 46 (22) Targeted therapy 12 (4) 0 (0) 12 (6) Others 14 (5) 0 (0) 14 (7) Diabetes ", "cite_spans": [{"start": 59, "end": 70, "text": "May 3, 2020", "ref_id": null}, {"start": 71, "end": 98, "text": ". . https://doi.org/10.1101", "ref_id": null}, {"start": 99, "end": 104, "text": "/2020", "ref_id": "BIBREF2"}], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "404"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. . https://doi.org/10. 1101 /2020 ", "cite_spans": [{"start": 94, "end": 98, "text": "1101", "ref_id": null}, {"start": 99, "end": 104, "text": "/2020", "ref_id": "BIBREF2"}], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "Ground glass opacity Yes vs. no 0.72 (0.37-1.40) 0.33 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)", "cite_spans": [], "ref_spans": [], "section": "CT findings"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. ", "cite_spans": [], "ref_spans": [], "section": "CT findings"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Clinical features of patients infected with 2019 novel 360 coronavirus in Wuhan, China. Lancet", "authors": [{"first": "C", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "", "volume": "395", "issn": "", "pages": "497--506", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Early Transmission Dynamics in Wuhan, China", "authors": [{"first": "Q", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Guan", "suffix": ""}, {"first": "P", "middle": [], "last": "Wu", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "The New England journal of medicine", "authors": [{"first": "Coronavirus-Infected", "middle": [], "last": "Pneumonia", "suffix": ""}], "year": 2020, "venue": "", "volume": "382", "issn": "", "pages": "1199--1207", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "World Health Organization. Coronavirus diease (COVID-19) pandemic", "authors": [], "year": 2020, "venue": "", "volume": "365", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "first systematic description of the clinical characteristics of COVID-19 in 116 China was reported on February, 2020, showing a fatality rate of 1.4% among the 1,099 117 Chinese patients. 4 Till April 02, 2020, the novel viral infection has caused 82,735 and 118 855,446 cumulative cases in China and worldwide, with 3,327 and 43,955 reported death,", "latex": null, "type": "figure"}, "FIGREF1": {"text": "patients who were newly admitted to 33 designated hospitals for 137 COVID-19 in Hubei province, China between December 17, 2019 and March 18, 2020 138 were included. The follow-up cutoff date was April 02, 2020. The patients were admitted 139 to the hospitals for suspicious or confirmed SARS-CoV-2 infection irrespective of their on-140 admission symptom levels, and all patients eventually got laboratory confirmed diagnosis 141 with COVID-19. The collection and tests of clinical specimens, diagnosis, treatment (anti-142 tumor and anti-infections), examinations, and severity level assessment (asymptomatic, 143 mild, moderate, severe, and critical cases) of COVID-19 were performed following the 144 latest edition of Novel Coronavirus Pneumonia Diagnosis and Treatment Plan released by 145 the National Health Commission & National Administration of Traditional Chinese 146 Medicine by assessment. Nasopharyngeal swabs were collected for pathogenic test using 147 RT-PCR assay to confirm the presence of 2019-nCoV nucleic acid. 148 Data of the demographic and clinicopathological characteristics, infection 149 symptoms, examination results (laboratory tests, chest CT scan, etc.), clinical treatments, 150 and survival outcomes were retrospectively collected from the electronic medical records 151", "latex": null, "type": "figure"}, "FIGREF3": {"text": "used to test the associations between different variables and the critical 183 and death cases. For univariable analysis, baseline characteristics were tested with blood 184 biochemistry variables transformed into categorical variables with the cutoffs upon the 185 clinical relevance. Variables that achieved a significant level with p < 0.05 and an odds 186 ratio (OR) > 3 in the univariable analysis were selected for multivariable logistic regression 187 using stepwise forward conditional mode. When strong correlations were present among 188 the variables that met the above criteria, only the one with the highest odds ratio entered 189 the multivariable analysis. All reported p values were two-tailed, and p < 0.05 was 190 considered statistically significant. The analyses were performed with the use of R software 191 (version 3.5.0, R Foundation for Statistical Computing) and GraphPad Prism software 192 (version 5.0, GraphPad Software Inc.).", "latex": null, "type": "figure"}, "FIGREF4": {"text": "The median age 197 of the overall patients was 63.0 (IQR, 55.0-70.0) years, and 50% were male patients. The 198 overall population harbored more than 20 types of tumor, including 51 (18%) with lung 199 cancer, 38 (13%) with breast cancer, and 34 (12%) with colorectal cancer, etc. The most 200 common comorbidities were hypertension (33%), diabetes (14%), and cardiovascular 201 disease (11%). At onset of illness, 6 (2%), 97 (34%), 108 (38%), and 72 (25%) of the 202 patients were asymptomatic, with mild, moderate, and severe symptoms, respectively. 203 Amongst all, 76 (27%) were former cancer patients who have undergone primary resection 204 for over five years without relapse, 207 (73%) were current cancer patients, including 101 205 .", "latex": null, "type": "figure"}, "FIGREF5": {"text": "210 scan presented ground glass opacity in 211 (75%) patients, interstitial thickening in 112 211 (40%) patients, consolidation in 71 (25%) patients, and reticular pattern in 60 (21%) 212 patients, which was similarly observed in the former and current cancer patients 213 (supplementary table S2).214 Prognosis and outcomes 215 For treatment against COVID-19, antiviral, antibacterial, hormone, and immunoglobulin 216 therapies were provided for 262 (93%), 233 (82%), 113 (40%), and 86 (30%) patients, 217 respectively. The clinical courses of the patients throughout hospitalization were provided 218 for the overall population (figure 1), the former cancer patients (supplementary figure S1), 219 and the current cancer patients (supplementary figure S2). The overall mortality rate was 220 18% (50/283), including 17% (47/283) deaths due to COVID-19. During hospitalization, 221 19 mild cases, 34 moderate cases, and 72 severe cases eventually developed severe (62 222 [22%]) and critical (63 [22%]) cases. Of the critical cases, 45 (71%) died by the last visit, 223 accounting for 90% of the overall death cases (figure 1). The most common complications 224 were ARDS (85, 30%), stroke (42, 15%), and acute heart failure (17, 6%). Non-invasive 225 and invasive mechanical ventilations were provided for 51 (18%) and 18 (6%) patients, 226 respectively. At the last follow up, there were 178 (63%) asymptomatic cases and 2 (1%) 227 severe cases (figure 1).", "latex": null, "type": "figure"}, "FIGREF6": {"text": "patients, respectively. The recovery degree as represented by the ratio of 232 asymptomatic patients by the last follow-up visit was 63% (178/283) in the overall 233 population, 68% (52/76) in the former cancer patients, and 61% (126/207) in the current 234 cancer patients, respectively. As shown, the worst prognosis was observed in the patients 235 with current lymphohematopoietic malignancies (LHM) including lymphoma (n = 8) and 236 leukemia (n = 9), followed by esophageal cancer (n = 9) and lung cancer (n = 51), with 237 a remission rate of 38%, 44%, 67%, and 70%, and a degree of recovery of 38%, 22%, 44%,238 and 54%, respectively (figure 2, supplementary table S3). In addition, the LHM patients 239 were more likely to develop severe or critical cases (59%, 10/17 vs 22%, 41/190) and 240 deaths (53%, 9/17 vs 18%, 34/190) compared to patients with solid tumors (supplementary 241 Table S4), and all the seven LHM patients with recent chemotherapy died. 242 The median hospitalization stay was 24 days for the overall survivors (figure 3A) 243 and the median duration from admission to death was 13.5 days in COVID-19 deceased 244 cases (figure 3B). The current cancer patients exhibited a longer median hospitalization 245 stay (26 days vs 25 days, figure 3C) and significantly higher risk of death compared to the 246 former cancer patients (OS, HR 2.45, 95%CI 1.10-5.44, log-rank p = .023), with a mortality 247 rate of 21% (43/207) and 9% (7/76), respectively (figure 3D). Of the 207 current cancer 248 patients, 95 (46%) have received recent anti-tumor treatments, including 46 (22%) with 249 chemotherapy, 23 (11%) with surgical resection, and 26 (13%) with other anti-tumor 250 treatments. Among them, the highest mortality rate was observed in the patients treated251", "latex": null, "type": "figure"}, "FIGREF7": {"text": "and discharged with 31-day hospitalization stay, and another patient with 256 stage IV urothelial cancer who had moderate symptoms as the worst status and got 257 discharged after recovery with 26 days of hospitalization stay.258 Risk factors 259 Logistic regression analyses were conducted to investigate the potential risk factors 260 associated with disease severity in COVID-19 cancer patients. Demographic and clinical 261 characteristics, symptoms, CT findings and laboratory findings were included for analysis. 262 Multivariable analysis indicated that lymphohematopoietic malignancies (p = 0.001), 263 severe symptoms at first clinical visit (p = 0.012), and elevated levels of neutrophil (> 264 6.3\u00d710 9 /mL, p = 3.00\u00d710 -6 ), direct bilirubin (DBIL) (> 7 \u03bcmol/L, p = 0.001), creatinine 265 (> 115 \u03bcM, p = 0.007), and troponin (> 5 ng/ml, p = 0.033) at baseline were independent 266 risk factors associated with the development of critical illness or deaths(table 2). No 267 significant association was observed between the cancer status (current vs former)", "latex": null, "type": "figure"}, "FIGREF8": {"text": "273 characteristics, clinical outcomes, and risk factors for death of COVID-19 in patients with 274 tumors. Our study highlighted the poorer prognosis of COVID-19 in cancer patients, which 275 may provide valuable clues for the patient management under the current coronavirus 276 .", "latex": null, "type": "figure"}, "FIGREF9": {"text": "283COVID-19 cases as reported in Hubei province (4.7%) over the same period (as of April284 02, 2020), 5 indicating the worse outcomes in the patients with a history of cancer when 285 infected by the novel coronavirus. 286 A statistically significantly shorter overall survival was observed in the current 287 cancer patients compared to the former cancer patients, and the difference was larger when 288 the patients received recent anti-tumor treatment, especially chemotherapy, which is most 289 likely to weaken the immune system among different treatments. For patients with LHM, 290 who often have a severely defective immune system upon the largely replacement of 291 normal functional immune cells by malignant cells, a higher prevalence was observed in 292", "latex": null, "type": "figure"}, "FIGREF10": {"text": "provided the first systematic investigations of the clinical characterization, 328 outcomes, and risk factors for disease severity of COVID-19 patients with malignancies. 329 The results indicated a potentially higher susceptibility and poorer prognosis of patients 330 with a history of cancer when infected with SARS-CoV-2. Given that there are no 331 confirmed effective drugs for the prevention or treatment of COVID-19 to date, strict 332 preventions and special cares are warranted for patients with malignancies to minimize the 333 potential risks and impacts from infections under the pandemic.", "latex": null, "type": "figure"}, "FIGREF11": {"text": "JW and JH contributed equally to this paper and are joint corresponding 336 authors. JW, QS, YC, ZW, QC, HG, and SC are joint first authors. All corresponding and 337 first authors contributed to study concept and design. JW, ZW, SC, QS, QC, GW, YuXu, 338 and ZZhao contributed to the acquisition, analysis, and interpretation of data. JW, ZW, SC, 339 GW, YuXu, and ZZhao wrote the first draft of the report. All authors approved the final 340 version of the report. JH and JW were responsible for the integrity and accuracy of the data 341 and is the guarantor. The corresponding authors attest that all listed authors meet authorship 342 criteria and that no others meeting the criteria have been omitted. 343 Funding: This work was supported by the CAMS Initiative for Innovative Medicine 344 (CAMS 2020-I2M-CoV19-004). The funding sources had no role in the design and conduct 345 of the study; collection, management, analysis, and interpretation of the data; preparation, 346 review, or approval of the manuscript; and decision to submit the manuscript for 347 publication.", "latex": null, "type": "figure"}, "FIGREF12": {"text": "W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With 378 Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA oncology. 2020. 379 10. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With 380 Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA oncology. Mar 25 2020. 381 11. World Health Organization. Clinical management of severe acute respiratory 382 infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized 385 with Severe Covid-19. The New England journal of medicine. Mar 18 2020. 386 13. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA: a cancer 387 journal for clinicians. Mar-Apr 2016;66(2):115-132. 388 14. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 389 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.", "latex": null, "type": "figure"}, "FIGREF13": {"text": "PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients 392 in the Seattle Region -Case Series. The New England journal of medicine.", "latex": null, "type": "figure"}, "TABREF0": {"text": "Former cancer patients were defined as the patients who were diagnosed with malignancies 158 and have received curative surgical resections over five years without recurrence till the 159 hospital admission for COVID-19. Fever was defined as an axillary temperature of 37.5\u00b0C160 or higher. Acute respiratory distress syndrome (ARDS) was defined based on the interim guidance for the management of critical COVID-19 by WHO. 11 Recent anti-tumor treatment were defined as the conventional anti-tumor treatment that were provided within 163 3 months before the hospital admission for COVID-19. The types of conventional antitumor treatment included: surgical resection, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and combinational therapy, etc. Critical cases were defined as patients 166 with ARDS and requiring mechanical ventilation or extracorporeal membrane oxygenation 167 (ECMO), shock, acute heart failure, acute myocardial infarction, or acute renal failure. Hospitalization stay was defined as the date from hospital admission for COVID-19 till 169 discharge. Remission was defined as either the decrease of at least one-level on disease 170 severity, the change of nucleic acid test results from positive to negative, or the improved absorption of inflammation upon pulmonary imaging. The overall survival (OS) was defined as the time from the date of first clinical visit for suspicious infection of SARS-", "latex": null, "type": "table"}, "TABREF1": {"text": "In our cohort of 283 cancer patients with COVID-19 infection, the median hospitalization stay was 26 days, which is longer than the previously reported 12 days 4 in the unselected COVID-19 cases and 16 days in the severe cases.12  Recent study reported that the mortality rate was 28.6% in 28 SARS-CoV-2 infected cancer patients, 8 our analysis further provided a mortality rate of 18%, with 9% in former cancer patients and 21% in current cancer patients, both higher than that of the overall cumulative mortality rate of", "latex": null, "type": "table"}, "TABREF2": {"text": "Competing interests: All authors declare no competing interests.Ethical approval: This study was approved by the Ethics Committee of the National Cancer Center (No. 20/061-2257, Beijing, China). The requirement for informed patient consent was waived by the ethics committee due to the urgent of data collection.Data sharing:The data that support the findings of this study are available from the corresponding author on reasonable request.The manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have", "latex": null, "type": "table"}, "TABREF4": {"text": "Demographic, clinical, laboratory findings of cancer patients at the first clinical visit.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>Total (n = 283) </td><td>Former cancer patients (n = 76) </td><td>Current cancer patients (n = 207) </td></tr><tr><td>Demographic and clinical characteristics </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Age </td><td>63.0 (55.0-70.0) </td><td>65.0 (60.0-73.0) </td><td>62.0 (53.0-69.0) </td></tr><tr><td>Sex Female </td><td>142 (50) </td><td>45 (59) </td><td>97 (47) </td></tr><tr><td>Male </td><td>141 (50) </td><td>31 (41) </td><td>110 (53) </td></tr><tr><td>Smoking history Current </td><td>11 (4) </td><td>1 (1) </td><td>10 (5) </td></tr><tr><td>Former </td><td>54 (19) </td><td>10 (13) </td><td>44 (21) </td></tr><tr><td>Never </td><td>216 (76) </td><td>65 (86) </td><td>151 (73) </td></tr><tr><td>NA </td><td>2 (1) </td><td>0 (0) </td><td>2 (1) </td></tr><tr><td>Drinking history </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Current </td><td>11 (4) </td><td>1 (1) </td><td>10 (5) </td></tr><tr><td>Former </td><td>41 (14) </td><td>5 (7) </td><td>36 (17) </td></tr><tr><td>Never </td><td>210 (74) </td><td>69 (91) </td><td>141 (68) </td></tr><tr><td>NA </td><td>21 (7) </td><td>1 (1) </td><td>20 (10) </td></tr><tr><td>Huanan market exposure </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>No </td><td>254 (90) </td><td>67 (88) </td><td>187 (90) </td></tr><tr><td>Yes </td><td>10 (4) </td><td>4 (5) </td><td>6 (3) </td></tr><tr><td>NA </td><td>19 (7) </td><td>5 (7) </td><td>14 (7) </td></tr><tr><td>Symptoms at the first visit </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Asymptomatic </td><td>6 (2) </td><td>1 (1) </td><td>5 (2) </td></tr><tr><td>Mild </td><td>97 (34) </td><td>26 (34) </td><td>71 (34) </td></tr><tr><td>Moderate </td><td>108 (38) </td><td>36 (47) </td><td>72 (35) </td></tr><tr><td>Severe </td><td>72 (25) </td><td>13 (17) </td><td>59 (29) </td></tr><tr><td>Pathology Lung cancer </td><td>51 (18) </td><td>5 (7) </td><td>46 (22) </td></tr><tr><td>Breast cancer </td><td>38 (13) </td><td>17 (22) </td><td>21 (10) </td></tr><tr><td>Colorectal cancer </td><td>34 (12) </td><td>14 (18) </td><td>20 (10) </td></tr><tr><td>Thyroid carcinoma </td><td>23 (8) </td><td>7 (9) </td><td>16 (8) </td></tr><tr><td>Gastric cancer </td><td>18 (6) </td><td>5 (7) </td><td>13 (6) </td></tr><tr><td>Cervical cancer </td><td>11 (4) </td><td>5 (7) </td><td>6 (3) </td></tr><tr><td>Leukemia </td><td>11 (4) </td><td>2 (3) </td><td>9 (4) </td></tr><tr><td>Urothelial cancer </td><td>11 (4) </td><td>4 (5) </td><td>7 (3) </td></tr><tr><td>Lymphoma </td><td>10 (4) </td><td>2 (3) </td><td>8 (4) </td></tr><tr><td>Esophageal cancer </td><td>9 (3) </td><td>0 (0) </td><td>9 (4) </td></tr><tr><td>Hepatocellular carcinoma </td><td>9 (3) </td><td>1 (1) </td><td>8 (4) </td></tr><tr><td>Head and neck cancer </td><td>7 (2) </td><td>4 (5) </td><td>3 (1) </td></tr><tr><td>Ovarian cancer </td><td>5 (2) </td><td>1 (1) </td><td>4 (2) </td></tr><tr><td>Prostate cancer </td><td>5 (2) </td><td>1 (1) </td><td>4 (2) </td></tr><tr><td>Sarcoma </td><td>5 (2) </td><td>1 (1) </td><td>4 (2) </td></tr><tr><td>Pancreatic cancer </td><td>4 (1) </td><td>0 (0) </td><td>4 (2) </td></tr><tr><td>Renal cell carcinoma </td><td>4 (1) </td><td>0 (0) </td><td>4 (2) </td></tr><tr><td>Others </td><td>28 (10) </td><td>7 (9) </td><td>21 (10) </td></tr><tr><td>Recent anti-cancer treatment No </td><td>188 (66) </td><td>76 (100) </td><td>112 (54) </td></tr><tr><td>Surgery </td><td>23 (8) </td><td>0 (0) </td><td>23 (11) </td></tr></table></body></html>"}, "TABREF6": {"text": "Data are median (IQR), or n (%). Abbreviations: NA=not applicable; COPD=chronic obstructive pulmonary disease; ALT=alanine aminotransferase; AST=aspartate aminotransferase; TBIL=total bilirubin. DBIL=direct bilirubin; APTT=activated partial thromboplastin time; CK-MB=creatine kinase-MB; CRP=C-reactive protein; hsCRP=high", "latex": null, "type": "table"}, "TABREF7": {"text": "Risk factors at the first clinical visit associated with critical ill or death.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>Comparison </td><td>Univariable OR (95%CI) </td><td>p value Multivariable OR (95%CI) </td><td>p value </td></tr><tr><td>\u00a0</td><td>Demographic and clinical characteristics </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Age year </td><td>&gt;65 vs. \u226465 </td><td>1.94 (1.12-3.37) </td><td>0.02 </td><td>\u00a0</td></tr><tr><td>Sex </td><td>Female vs. male </td><td>0.67 (0.39-1.16) </td><td>0.16 </td><td>\u00a0</td></tr><tr><td>Smoking history </td><td>No (ref.) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Current vs. ref. </td><td>0.78 (0.16-3.72) </td><td>0.75 </td><td>\u00a0</td></tr><tr><td>Drinking history </td><td>Former vs. ref. </td><td>1.61 (0.83-3.10) </td><td>0.16 </td><td>\u00a0</td></tr><tr><td>No (ref.) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Current vs. ref. </td><td>0.75 (0.16-3.59) </td><td>0.72 </td><td>\u00a0</td></tr><tr><td>Huanan market exposure </td><td>Former vs. ref. </td><td>1.40 (0.66-2.94) </td><td>0.38 </td><td>\u00a0</td></tr><tr><td>Yes vs. no </td><td>0.77 (0.16-3.74) </td><td>0.75 </td><td>\u00a0</td></tr><tr><td>Cancer history </td><td>Former (ref.) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Current vs. ref. </td><td>1.98 (0.99-3.94) </td><td>0.052 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>LHM vs. ref. </td><td>9.78 (3.03-31.51) </td><td>1.34*10-4 40.02 (4.35-368.69) </td><td>0.001 </td></tr><tr><td>\u00a0</td><td>Lung cancer vs. ref. </td><td>3.13 (1.32-7.38) </td><td>0.009 1.69 (0.32-8.95) </td><td>0.54 </td></tr><tr><td>Recent anti-cancer treatment </td><td>Other cancers vs. ref. </td><td>1.29 (0.61-2.70) </td><td>0.51 1.00 (0.22-4.52) </td><td>1.00 </td></tr><tr><td>No treatment (ref.) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Any treatment vs. ref. </td><td>1.93 (1.11-3.38) </td><td>0.021 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Surgery vs. ref. </td><td>1.43 (0.53-3.88) </td><td>0.48 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Chemotherapy vs. ref. </td><td>2.38 (1.18-4.78) </td><td>0.015 </td><td>\u00a0</td></tr><tr><td>Diabetes </td><td>Others vs. ref. </td><td>1.71 (0.69-4.20) </td><td>0.24 </td><td>\u00a0</td></tr><tr><td>Yes vs. no </td><td>0.42 (0.16-1.13) </td><td>0.085 </td><td>\u00a0</td></tr><tr><td>Hypertension </td><td>Yes vs. no </td><td>1.58 (0.90-2.78) </td><td>0.11 </td><td>\u00a0</td></tr><tr><td>Cardiovascular comorbidity </td><td>Yes vs. no </td><td>2.84 (1.33-6.07) </td><td>0.007 </td><td>\u00a0</td></tr><tr><td>Cerebrovascular comorbidity </td><td>Yes vs. no </td><td>0.83 (0.27-2.60) </td><td>0.75 </td><td>\u00a0</td></tr><tr><td>COPD </td><td>Yes vs. no </td><td>2.26 (0.88-5.77) </td><td>0.090 </td><td>\u00a0</td></tr><tr><td>Chronic liver disease </td><td>Yes vs. no </td><td>0.86 (0.23-3.16) </td><td>0.82 </td><td>\u00a0</td></tr><tr><td>Chronic renal disease </td><td>Yes vs. no </td><td>0.78 (0.16-3.78) </td><td>0.76 </td><td>\u00a0</td></tr><tr><td>Symptoms </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Symptoms at the first visit </td><td>Severe vs. non-severe </td><td>5.10 (2.82-9.23) </td><td>7.16*10-8 5.43 (1.46-20.24) </td><td>0.012 </td></tr><tr><td>Fever </td><td>Yes vs. no </td><td>0.77 (0.42-1.42) </td><td>0.40 </td><td>\u00a0</td></tr><tr><td>Cough </td><td>Yes vs. no </td><td>1.51 (0.82-2.81) </td><td>0.19 </td><td>\u00a0</td></tr><tr><td>Sputum </td><td>Yes vs. no </td><td>2.12 (1.22-3.70) </td><td>0.008 </td><td>\u00a0</td></tr><tr><td>Dyspnea </td><td>Yes vs. no </td><td>4.14 (2.31-7.39) </td><td>2.00*10-6 </td><td>\u00a0</td></tr><tr><td>Fatigue </td><td>Yes vs. no </td><td>1.74 (1.00-3.03) </td><td>0.052 </td><td>\u00a0</td></tr><tr><td>Headache </td><td>Yes vs. no </td><td>1.53 (0.56-4.19) </td><td>0.41 </td><td>\u00a0</td></tr><tr><td>Muscle ache </td><td>Yes vs. no </td><td>0.54 (0.20-1.46) </td><td>0.22 </td><td>\u00a0</td></tr><tr><td>Sore throat </td><td>Yes vs. no </td><td>1.18 (0.36-3.83) </td><td>0.79 </td><td>\u00a0</td></tr><tr><td>Diarrhea </td><td>Yes vs. no </td><td>0.63 (0.25-1.59) </td><td>0.33 </td><td>\u00a0</td></tr><tr><td>Nausea </td><td>Yes vs. no </td><td>0.46 (0.13-1.59) </td><td>0.22 </td><td>\u00a0</td></tr><tr><td>Sneeze </td><td>Yes vs. no </td><td>3.28 (0.45-23.72) </td><td>0.24 </td><td>\u00a0</td></tr><tr><td>Nasal congestion </td><td>Yes vs. no </td><td>1.07 (0.11-10.47) </td><td>0.95 </td><td>\u00a0</td></tr><tr><td>Nasal discharge </td><td>Yes vs. no </td><td>1.97 (0.46-8.46) </td><td>0.36 </td><td>\u00a0</td></tr><tr><td>CT findings </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Ground glass opacity </td><td>Yes vs. no </td><td>0.72 (0.37-1.40) </td><td>0.33 </td></tr></table></body></html>"}, "TABREF8": {"text": ". https://doi.org/10.1101//doi.org/10. /2020 p values were calculated by univariable or multivariable logistic regression. Abbreviations: NA=not applicable.COPD=chronic obstructive pulmonary disease. ALT=alanine aminotransferase; AST=aspartate aminotransferase; TBIL=total bilirubin; DBIL=direct bilirubin; APTT=activated partial thromboplastin time; CK-MB=creatine kinase-MB;", "latex": null, "type": "table"}}, "back_matter": [{"text": "CRP=C-reactive protein; hsCRP=high sensitivity C-reactive protein; LHM= Lymphohematopoietic cancer.", "cite_spans": [], "ref_spans": [], "section": "408"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 3, 2020. shown from their onset illness (left), most severe severity level (middle), to last follow-up visit (right).", "cite_spans": [], "ref_spans": [], "section": "410"}, {"text": "The patients with different severity levels were demonstrated in different colors. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "413"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. ", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "424"}, {"text": "The copyright holder for this preprint this version posted May 3, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 3, 2020. . https://doi.org/10. 1101 /2020 ", "cite_spans": [{"start": 368, "end": 372, "text": "1101", "ref_id": null}, {"start": 373, "end": 378, "text": "/2020", "ref_id": "BIBREF2"}], "ref_spans": [], "section": "(which was not certified by peer review)"}]}